Cochrane · systematic review · CD008653
Febuxostat for treating chronic gout
Tayar, JH, Lopez‐Olivo, MA, Suarez‐Almazor, ME · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
24
No studies
18
Included studies
NR
No studies 18 · 42.9%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 14.3%Moderate 11 · 26.2%High 7 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Febuxostat 40 mg/day versus placebo
Population: patients with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gout flares Febuxostat 40 mg/day vs placebo | RR 0.95 [0.52, 1.7] | 1 study · 75 participants | Low |
Serum uric acid <6.0 mg/dL at final visit Febuxostat 40 mg/day vs placebo | RR 40.1 [2.5, 639.1] | 1 study · 69 participants | Low |
Pain Febuxostat 40 mg/day vs placebo | no estimate extracted | NR | No studies |
Patient global assessment Febuxostat 40 mg/day vs placebo | no estimate extracted | NR | No studies |
Health Related Quality of Life Febuxostat 40 mg/day vs placebo | no estimate extracted | NR | No studies |
Serious Adverse Events Febuxostat 40 mg/day vs placebo | RR 1 [0, 0] | 1 study · 75 participants | Moderate |
Discontinuations due to adverse events Febuxostat 40 mg/day vs placebo | RR 1 [0.07, 15.8] | 1 study · 75 participants | Moderate |
Febuxostat 80 mg/day versus placebo
Population: patients with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gout flares Febuxostat 80 mg/day vs placebo | RR 1.32 [0.96, 1.8] | 2 studies · 474 participants | Low |
Serum uric acid <6.0 mg/dL at final visit Febuxostat 80 mg/day vs placebo | RR 68.9 [13.8, 343.9] | 2 studies · 332 participants | Low |
Pain Febuxostat 80 mg/day vs placebo | no estimate extracted | NR | No studies |
Patient global assessment Febuxostat 80 mg/day vs placebo | no estimate extracted | NR | No studies |
Health Related Quality of Life Febuxostat 80 mg/day vs placebo | no estimate extracted | NR | No studies |
Serious Adverse Events Febuxostat 80 mg/day vs placebo | RR 2.8 [0.72, 10.7] | 2 studies · 479 participants | Moderate |
Discontinuations due to adverse events Febuxostat 80 mg/day vs placebo | RR 1.8 [0.74, 4.5] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day versus placebo
Population: patients with chronic cout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gout flares Febuxostat 120 mg/day vs placebo | RR 1.7 [1.3, 2.3] | 2 studies · 479 participants | Moderate |
Serum uric acid <6.0 mg/dL at final visit Febuxostat 120 mg/day vs placebo | RR 80.7 [16, 405.5] | 2 studies · 356 participants | Low |
Pain Febuxostat 120 mg/day vs placebo | no estimate extracted | NR | No studies |
Patient global assessment Febuxostat 120 mg/day vs placebo | no estimate extracted | NR | No studies |
Health Related Quality of Life Febuxostat 120 mg/day vs placebo | no estimate extracted | NR | No studies |
Serious Adverse events Febuxostat 120 mg/day vs placebo | RR 2.7 [0.7, 10.2] | 2 studies · 479 participants | Moderate |
Discontinuations due to adverse events Febuxostat 120 mg/day vs placebo | RR 1.7 [0.67, 4.1] | 2 studies · 479 participants | Moderate |
Febuxostat 40 mg/day versus allopurinol
Population: patients with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gout flares Febuxostat 40 mg/day vs allopurinol | RR 0.97 [0.57, 1.65] | 1 study · 1324 participants | High |
Serum uric acid <6.0 mg/dL at final visit Febuxostat 40 mg/day vs allopurinol | RR 1.1 [0.94, 1.2] | 1 study · 1324 participants | Moderate |
Pain Febuxostat 40 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Patient global assessment Febuxostat 40 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Health Related Quality of Life Febuxostat 40 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Serious Adverse Events Febuxostat 40 mg/day vs allopurinol | RR 0.61 [0.35, 1.07] | 1 study · 1513 participants | High |
Discontinuations due to adverse events Febuxostat 40 mg/day vs allopurinol | RR 1.2 [0.9, 1.7] | 1 study · 1513 participants | High |
Febuxostat 80 mg/day versus allopurinol
Population: patients with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gout flares Febuxostat 80 mg/day vs allopurinol | RR 1.1 [0.98, 1.3] | 3 studies · 2325 participants | High |
Serum uric acid <6.0 mg/dL at final visit Febuxostat 80 mg/day vs allopurinol | RR 1.8 [1.6, 2.2] | 3 studies · 2193 participants | Low |
Pain Febuxostat 80 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Patient global assessment Febuxostat 80 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Health Related Quality of Life Febuxostat 80 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Serious Adverse Events Febuxostat 80 mg/day vs allopurinol | RR 0.91 [0.34, 2.4] | 3 studies · 1044 participants | Moderate |
Discontinuations due to adverse events Febuxostat 80 mg/day vs allopurinol | RR 1.3 [0.79, 2.1] | 3 studies · 1044 participants | Moderate |
Febuxostat 120 mg/day versus allopurinol
Population: patients with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gout flares Febuxostat 120 mg/day vs allopurinol | RR 1.3 [0.87, 1.9] | 2 studies · 986 participants | High |
Serum uric acid <6.0 mg/dL at final visit Febuxostat 120 mg/day vs allopurinol | RR 2.2 [1.9, 2.5] | 2 studies · 880 participants | Moderate |
Pain Febuxostat 120 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Patient global assessment Febuxostat 120 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Health Related Quality of Life Febuxostat 120 mg/day vs allopurinol | no estimate extracted | NR | No studies |
Serious Adverse Events Febuxostat 120 mg/day vs allopurinol | RR 1.2 [0.7, 1.93] | 3 studies · 1041 participants | High |
Discontinuations due to adverse events Febuxostat 120 mg/day vs allopurinol | RR 1.6 [0.49, 5] | 3 studies · 1041 participants | High |